DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Daily DPP-4 inhibitor
Drug: Trelagliptin

First Posted Date: 2017-01-09

Last Posted Date: 2023-12-22

Lead Sponsor: Takeda

Target Recruit Count: 219

Registration Number: NCT03014479

Locations: 🇯🇵
Takeda Selected Site 1, Suita, Osaka, Japan
🇯🇵
Takeda Selected Site 13, Shinagawa-ku, Tokyo, Japan
🇯🇵
Takeda Selected Site 8, Shinjuku-ku, Tokyo, Japan

and more 24 locations

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: GnRH agonist
Drug: Enantone

First Posted Date: 2016-12-15

Last Posted Date: 2022-03-16

Lead Sponsor: Takeda

Target Recruit Count: 108

Registration Number: NCT02993926

Locations: 🇨🇳
The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Childrens Hospital of Hunan province, Changsha, Hunan, China
🇨🇳
Jiangsu Province Hosptial, Nanjing, Jiangsu, China

and more 2 locations

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Alogliptin
Drug: Alogliptin FDC With Pioglitazone
Drug: Alogliptin FDC With Metformin

First Posted Date: 2016-12-12

Last Posted Date: 2019-04-19

Lead Sponsor: Takeda

Target Recruit Count: 593

Registration Number: NCT02989649

A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)

Completed

Conditions: Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases

First Posted Date: 2016-12-08

Last Posted Date: 2020-09-25

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT02986724

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Hodgkin Disease

Interventions: Drug: Brentuximab vedotin
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine

First Posted Date: 2016-12-01

Last Posted Date: 2025-03-04

Lead Sponsor: Takeda

Target Recruit Count: 59

Registration Number: NCT02979522

Locations: 🇧🇷
ICr - Instituto da Crianca - HCFMUSP, Sao Paulo, Brazil
🇮🇹
Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma, Italy
🇧🇷
Hospital Santa Marcelina, Sao Paulo, Brazil

and more 11 locations

rVWF IN PROPHYLAXIS

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: von Willebrand factor (Recombinant)
Biological: Antihemophilic Factor (Recombinant)

First Posted Date: 2016-11-25

Last Posted Date: 2021-08-06

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT02973087

Locations: 🇫🇷
Hôpital Morvan, Brest, Finistere, France
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇫🇷
CHU Dijon - Hopital du Bocage, Dijon cedex, France

and more 28 locations

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2016-11-23

Last Posted Date: 2019-07-11

Lead Sponsor: Takeda

Target Recruit Count: 123

Registration Number: NCT02972632

Locations: 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸
Novex Clinical Research, LLC, New Bedford, Massachusetts, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 22 locations

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Phase 3

Withdrawn

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: TCV-116CCB
Drug: Amlodipine Placebo
Drug: TCV-116CCB Placebo

First Posted Date: 2016-11-21

Last Posted Date: 2017-06-09

Lead Sponsor: Takeda

Registration Number: NCT02969265

Locations: 🇨🇳
The Xiangya Hospitalof Central South University, Changsha, Hunan, China
🇨🇳
People's Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 22 locations

Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

Completed

Conditions: Diabetes Mellitus, Type 2, Cancer

Interventions: Drug: Pioglitazone

First Posted Date: 2016-11-08

Last Posted Date: 2018-03-07

Lead Sponsor: Takeda

Target Recruit Count: 236507

Registration Number: NCT02958956

Epidemiologic Study Of Diabetes And Cancer Risk

Completed

Conditions: Diabetes Mellitus, Type 2, Cancer

Interventions: Other: No Intervention

First Posted Date: 2016-11-08

Last Posted Date: 2018-03-07

Lead Sponsor: Takeda

Target Recruit Count: 2738161

Registration Number: NCT02958995

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy